NTIDC NTIDC
  • Home
  • Providers
  • Services
  • Research
    • Infectious Disease Clinical Trials & Research
    • Clinical Trial Sponsors
    • Infectious Diseases Research Staff
    • Hepatitis Research
    • HIV Research
    • STI Research
  • Pharmacy
  • Make Appointment
  • Patient Info
  • Contact
ViiV Healthcare Reports Positive Phase III Study Results
September 12, 2019December 13, 2020

ViiV Healthcare Reports Positive Phase III Study Results

NTIDC research is proud to be the only site in Dallas that has been dosing with long-acting, injectable HIV-treatment since 2014.

Read More
by NTIDC-EmpireDDIn NTIDC News
11
Gilead’s New Capsid Inhibitor in Early Trials
June 14, 2019December 13, 2020

Gilead’s New Capsid Inhibitor in Early Trials

Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.

Read More
by NTIDC-EmpireDDIn NTIDC News
10
Stem Cell Transplants Leads To Likely Cured HIV Patients
April 10, 2019December 13, 2020

Stem Cell Transplants Leads To Likely Cured HIV Patients

At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a second case of an HIV positive adult cleared of the HIV virus after he received a bone marrow transplant from an HIV resistant donor was presented.

Read More
by NTIDC-EmpireDDIn NTIDC News
10
The DISCOVER Trial, a Phase 3 Study Shows Results In Descovy (TAF/FTC) As An Effective Alternative To Truvada (TDF/FTC).
April 06, 2019December 13, 2020

The DISCOVER Trial, a Phase 3 Study Shows Results In Descovy (TAF/FTC) As An Effective Alternative To Truvada (TDF/FTC).

The DISCOVER trial was presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. The trial’s Phase 3, 96-week results for an updated formulation of PrEP compared to the current formulation was equally effective.

Read More
by NTIDC-EmpireDDIn NTIDC News
10

Latest News

  • Latest
  • ViiV Healthcare Reports Positive Phase III Study Results
    ViiV Healthcare Reports Positive Phase III Study ResultsSeptember 12, 2019
  • Gilead’s New Capsid Inhibitor in Early Trials
    Gilead’s New Capsid Inhibitor in Early TrialsJune 14, 2019
  • Stem Cell Transplants Leads To Likely Cured HIV Patients
    Stem Cell Transplants Leads To Likely Cured HIV PatientsApril 10, 2019

Downtown Dallas Location

3409 Worth Street Suite 710DallasTexas75246United States
https://www.infectiousdiseases.com214-823-2533
© 2019 North Texas Infectious Disease Consultants | All Rights Reserved